Morindone as a potential therapeutic compound targeting TP53 and KRAS mutations in colorectal cancer cells

In conclusion, morindone could be a competitive therapeutic agent in CRC by exhibiting multiple mechanism of anti-cancer actions.PMID:38423379 | DOI:10.1016/j.cbi.2024.110928

Source: Chemico-Biological Interactions - February 29, 2024 Category: Molecular Biology Authors: Cheok Wui Chee Najihah Mohd Hashim Nurshamimi Nor Rashid Source Type: research